Samsung Bioepis Flags 25% YoY Biosimilar Growth in Immunology Segment
Event summary
- 96 biosimilars approved across 21 unique biological molecules in the US as of June 2026, with 71 (74%) launched.
- Immunology biosimilars (adalimumab, tocilizumab, ustekinumab) show 25% YoY market penetration growth.
- Ustekinumab biosimilar penetration outpaces adalimumab despite similar pharmacy benefit coverage.
- Bevacizumab and ranibizumab biosimilars demonstrate sharp ASP increases while maintaining market share.
The big picture
Samsung Bioepis' report highlights accelerating biosimilar adoption in immunology, driven by pricing reforms and product differentiation. The 25% YoY growth in key molecules signals shifting dynamics in a market increasingly focused on transparency and cost accountability. With 74% of approved biosimilars now launched, the sector's maturation is creating both opportunities and competitive pressures.
What we're watching
- Regulatory Impact
- How 340B Drug Pricing Program reforms will reshape biosimilar market dynamics.
- Market Differentiation
- Whether ustekinumab biosimilars can sustain faster penetration than adalimumab.
- Pricing Strategy
- The pace at which ASP increases will affect long-term market share stability.
Related topics